The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Vaccine

• Publication date

  2008-03-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2008.01.034PMID 18294742
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Access to vaccine technologies in developing countries: Brazil and India.

  2007cited by this paper
• Managing the effect of TRIPS on availability of priority vaccines.

  2006cited by this paper
• Monitoring Financial Flows for Health Research. Geneva: Global Forum for Health Research, World Health Organization, 2001. 57pp. ISBN 2-940286- 05-1. [The full text is available on the web site http://www.globalforumhealth.org]

  2002cited by this paper
• Developing Country Vaccine Manufacturers Network (DCVMN), 26-27 April 2001, Bandung, Indonesia.

  2001cited by this paper
• A systematic method for evaluating the potential viability of local vaccine producers.

  1997cited by this paper
• Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates

  1980cited by this paper
• Haemophilus influenzae type B polysaccharide-protein conjugates: model for a new generation of capsular polysaccharide vaccines.

  1980cited by this paper

• Voorkomen is beter dan genezen

  2024cites this paper
• Success from the South: the rotavirus vaccine story and its lessons.

  2023cites this paper
• Equitable access to COVID-19 vaccine distribution – the case of the Andean Community

  2023cites this paper
• Voorkomen is beter dangenezen

  2023cites this paper
• Market Shaping and Market Access in the Global Vaccines Market: Approaches for the Future

  2021cites this paper
• The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization

  2020cites this paper
• A situation analysis of the state of supply of in vitro diagnostics in Low-Income Countries

  2020cites this paper
• Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan

  2020cites this paper
• World Pneumonia Day 2011-2016: Twitter contents and retweets.

  2018cites this paper
• Assessing the Importance of Domestic Vaccine Manufacturing Centers: An Overview of Immunization Programs, Vaccine Manufacture, and Distribution

  2018cites this paper
• Safety and immunogenicity of the novel seasonal preservative‐ and adjuvant‐free influenza vaccine: Blind, randomized, and placebo‐controlled trial

  2018cites this paper
• Viability of local vaccine production in developing countries: An economic analysis of cost structures, revenue sizes, market shares and vaccine prices

  2017influential citation
• The Right To Health and access to pandemic influenza vaccines : procurement options for developing states

  2016cites this paper
• Towards a sustainable, quality and affordable Haemophilus influenzae type b vaccine for every child in the world

  2016cites this paper
• 1 OF VACCINE PROCESS

  2015cites this paper
• Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial

  2015cites this paper
• History of Vaccine Process Development

  2014cites this paper
• Preclinical evaluation of a Haemophilus influenzae type b conjugate vaccine process intended for technology transfer

  2014cites this paper
• Enhancing the Work of the Department of Health and Human Services National Vaccine Program in Global Immunization: Recommendations of the National Vaccine Advisory Committee

  2014cites this paper
• The rise of companies from emerging markets in global health governance: Opportunities and challenges

  2014cites this paper
• Measles vaccination before the measles-mumps-rubella vaccine.

  2013cites this paper
• Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all.

  2013cites this paper
• Vaccinology capacity building in Europe for innovative platforms serving emerging markets

  2013cites this paper
• An International Perspective on Vaccine Safety

  2013cites this paper
• Vaccine Manufacturers Network : Doing good by making igh-quality vaccines affordable for all

  2013cites this paper
• Vaccine production training to develop the workforce of foreign institutions supported by the BARDA influenza vaccine capacity building program.

  2013cites this paper
• Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries.

  2012cites this paper
• Technology transfer in human vaccinology: a retrospective review on public sector contributions in a privatizing science field.

  2012cites this paper
• Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains.

  2012cites this paper
• Development of health biotechnology in developing countries: can private-sector players be the prime movers?

  2012cites this paper
• An international technology platform for influenza vaccines.

  2011cites this paper
• Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.

  2011cites this paper
• Challenges facing the successful introduction of plant-derived vaccines as an alternative or complement to conventional vaccines

  2011influential citation
• A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more.

  2011cites this paper
• A global road map is needed for vaccine research, development, and deployment.

  2011cites this paper
• New conjugate vaccines for the prevention of pneumococcal disease in developing countries.

  2011cites this paper
• Industrial development in a high tech sector of a developing country: new directions and the unfinished technological transition in the Brazilian vaccine industry

  2010cites this paper
• Haemophilus influenzae type b conjugate vaccines: Considerations for vaccination schedules and implications for developing countries

  2010cites this paper
• The manufacture and supply of dengue vaccine

  2010cites this paper
• China’s emerging vaccine industry

  2010influential citation
• Giving developing countries the best shot : An overview of vaccine access and R & D

  2010cites this paper
• Vaccines for all: Institut Pasteur Vaccinology Course, 2010

  2010cites this paper
• Stability testing of vaccines: Developing Countries Vaccine Manufacturers' Network (DCVMN) perspective.

  2009cites this paper
• Emerging markets & emerging needs: developing countries vaccine manufacturers' perspective & its current status.

  2009cites this paper
• Challenges and potential solutions to innovative vaccine development for developing countries

  2009cites this paper
• Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS

  2009cites this paper
• Evaluation of rotavirus vaccines in Asia--are there lessons to be learnt?

  2009cites this paper
• Model for product development of vaccines against neglected tropical diseases: a vaccine against human hookworm

  2008cites this paper
• Vaccines and global stability: achievements and challenges

  2008cites this paper
• The global strategy to cope with H5N1: the property rights caveat

  2008influential citation